Literature DB >> 29956203

Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC.

Ken Liu1,2,3, Geoffrey W McCaughan4,5,6.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world and will soon become the number one cause of hepatocellular carcinoma (HCC), liver transplantation and liver-related mortality. The disease often occurs in the setting of metabolic conditions such as obesity and type II diabetes mellitus. These same metabolic drivers are also risk factors for NAFLD associated HCC which can occur even in the absence of cirrhosis or advanced fibrosis and appears to be phenotypically different to HCCs arising from other chronic liver diseases. The frequencies of liver-related events and HCC among NAFLD patients is low, especially when compared to cardiovascular disease and extrahepatic malignancies. However, the large denominator of total patients affected with NAFLD means that these events will impose an enormous clinical and economic burden on our society. Moreover, this burden is expected to rise further in the future. Therefore, the global NAFLD epidemic has arrived at our doorstep and demands our attention.

Entities:  

Keywords:  Economic burden; Epidemiology; Hepatocellular carcinoma; Metabolic syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Mesh:

Year:  2018        PMID: 29956203     DOI: 10.1007/978-981-10-8684-7_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma.

Authors:  Jian Wang; Cun-Di Li; Lin Sun
Journal:  Biomolecules       Date:  2020-02-14

Review 2.  Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology.

Authors:  Davide Gnocchi; Carlo Custodero; Carlo Sabbà; Antonio Mazzocca
Journal:  J Mol Med (Berl)       Date:  2019-04-05       Impact factor: 4.599

3.  Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.

Authors:  Zhenyu Hou; Keyun Zhu; Xuejiao Yang; Ping Chen; Wei Zhang; Yunlong Cui; Xiaolin Zhu; Tianqiang Song; Qiang Li; Huikai Li; Ti Zhang
Journal:  Ann Transl Med       Date:  2020-09

4.  Plant Sterol Ester of α-Linolenic Acid Attenuates Nonalcoholic Fatty Liver Disease by Rescuing the Adaption to Endoplasmic Reticulum Stress and Enhancing Mitochondrial Biogenesis.

Authors:  Hao Han; Yan Guo; Xiaoyu Li; Dongxing Shi; Tingli Xue; Linqi Wang; Yanyan Li; Mingming Zheng
Journal:  Oxid Med Cell Longev       Date:  2019-12-12       Impact factor: 6.543

Review 5.  Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.

Authors:  Diwakar Suresh; Akshatha N Srinivas; Divya P Kumar
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

6.  Comparison of obesity-related indices for identifying nonalcoholic fatty liver disease: a population-based cross-sectional study in China.

Authors:  Fangfei Xie; Yuyu Pei; Quan Zhou; Deli Cao; Yun Wang
Journal:  Lipids Health Dis       Date:  2021-10-10       Impact factor: 3.876

7.  Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.

Authors:  Zhenyu Hou; Keyun Zhu; Xuejiao Yang; Hongyuan Zhou; Ping Chen; Ge Yu; Xiaolin Zhu; Yunlong Cui; Tianqiang Song; Qiang Li; Huikai Li; Ti Zhang
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.